<DOC>
	<DOCNO>NCT00529048</DOCNO>
	<brief_summary>Patients T2DM lac sufficient incretin response oral glucose intake . It test use 50g glucose . We n't know patient T2DM capable regulating incretin effect like healthy people respond different amount glucose intake . The aim present study quantify incretin effect healthy subject patient T2DM increase amount oral glucose challenge . The proposed study answer important question mechanisms underlie T2DM importance relation future preventive- treatment strategy .</brief_summary>
	<brief_title>Quantification Incretin Effect Healthy Subjects Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The impaired incretin effect patient type 2 diabetes mellitus ( T2DM ) previously evaluate use glucose load 50 g , uncertain whether patient T2DM capable regulating incretin effect equivalent healthy subject . Furthermore , great interest quantify secretion GIP GLP-1 increase glucose load patient T2DM healthy subject order evaluate whether increase secretion one two incretin hormone contribute regulation incretin effect . The aim present study quantify incretin effect healthy subject patient T2DM increase amount oral glucose challenge correspond isoglycemic iv glucose challenge . The proposed study answer important question pathophysiology underlie T2DM importance relation future preventive- treatment strategy . Eight patient T2DM 8 match healthy subject evaluate oral glucose tolerance test ( OGTT ) use increase glucose load ( 25 , 50 100 g glucose ) isoglycemic iv glucose tolerance test imitate glucose concentration obtain oral glucose load . The result describe regulation incretin effect patient T2DM , thereby , contribute clarification pathophysiology postprandial hyperglycemia characterize patient .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Cases Caucasians T2DM accord WHO 's criterion Normal Hemoglobin Agree participate ( orally write ) HbA1c : 6.59 % BMI : 2335 kg/m2 Cases Liver disease ( ALAT &gt; 2 x normal level ) Diabetic nephropathy ( screatinin &gt; 130 µM albuminuria ) Diabetic neuropathy ( anamnestic ) Proliferative diabetic retinopathy ( anamnestic ) Medical treatment witch stop 12 hour Pregnancy breastfeed Treatment Insulin glitazones Control group Caucasians Normal oral glucose tolerance accord WHO 's criterion Normal Hemoglobin Agree participate ( orally write ) BMI : 2335 kg/m2 Control group Liver disease ( ALAT &gt; 2 x normal level ) Impaired function kidney ( screatinin &gt; 130 µM albuminuria ) Directly relate til someone suffer diabetes mellitus Medical treatment witch stop 12 hour Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Incretin effect</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Gastric Inhibitory Polypeptide</keyword>
</DOC>